AKBAAkebia Therapeutics, Inc.

AKBA Stock Price, Valuation & Chart | Akebia Therapeutics, Inc.

Compare

$0.980+0.04 (+3.77%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology AKBA intrinsic value AKBA calculated fair value vs price

Overview Financials Dividends Ratios

AKBA Historical price chart

AKBA Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization262.97M

PE Ratio-10.0

EPS-0.1

Trading Volume12.84M

Today's High/Low1.01/0.95

Dividend Yield0.00

52 Week High/Low3.2/0.81

Shares Outstanding268.26M

AKBA Financial Statement

AKBA Analyst ratings

AKBA Analysis & performance metrics

AKBA Company profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead…

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis…

AKBA Management team

Name

Position

Nicholas Grund

Senior Vice President & Chief Commercial Officer

Carolyn Rucci

Senior Vice President of Legal, General Counsel & Secretary

Richard C. Malabre

Chief Accounting Officer

Kimberly Garko

Senior Vice President & Chief Technical Officer

Erik John Ostrowski M.B.A.CFO

Chief Business Officer, Senior Vice President, Chief Financial Officer & Treasurer

Steven Keith Burke M.D.

Senior Vice President of Research & Development and Chief Medical Officer

John P. Butler MBACEO

Chief Executive Officer, President & Director

Tracey Vetterick

Vice President of Portfolio Strategy & Corporate Administration

Name

Position

Nicholas Grund

Senior Vice President & Chief Commercial Officer

Carolyn Rucci

Senior Vice President of Legal, General Counsel & Secretary

Richard C. Malabre

Chief Accounting Officer

Kimberly Garko

Senior Vice President & Chief Technical Officer

Erik John Ostrowski M.B.A.CFO

Chief Business Officer, Senior Vice President, Chief Financial Officer & Treasurer

Steven Keith Burke M.D.

Senior Vice President of Research & Development and Chief Medical Officer

John P. Butler MBACEO

Chief Executive Officer, President & Director

Tracey Vetterick

Vice President of Portfolio Strategy & Corporate Administration

Management Team

Nicholas Grund

Senior Vice President & Chief Commercial Officer

Carolyn Rucci

Senior Vice President of Legal, General Counsel & Secretary

Richard C. Malabre

Chief Accounting Officer

Kimberly Garko

Senior Vice President & Chief Technical Officer

Erik John Ostrowski M.B.A.CFO

Chief Business Officer, Senior Vice President, Chief Financial Officer & Treasurer

Steven Keith Burke M.D.

Senior Vice President of Research & Development and Chief Medical Officer

John P. Butler MBACEO

Chief Executive Officer, President & Director

Tracey Vetterick

Vice President of Portfolio Strategy & Corporate Administration

Management

Nicholas Grund

Senior Vice President & Chief Commercial Officer

Carolyn Rucci

Senior Vice President of Legal, General Counsel & Secretary

Richard C. Malabre

Chief Accounting Officer

Kimberly Garko

Senior Vice President & Chief Technical Officer

Erik John Ostrowski M.B.A.CFO

Chief Business Officer, Senior Vice President, Chief Financial Officer & Treasurer

Steven Keith Burke M.D.

Senior Vice President of Research & Development and Chief Medical Officer

John P. Butler MBACEO

Chief Executive Officer, President & Director

Tracey Vetterick

Vice President of Portfolio Strategy & Corporate Administration

Total 8 executives

AKBA Frequently asked questions

What is Akebia Therapeutics, Inc. (AKBA) Stock Price?

Current stock price of Akebia Therapeutics, Inc. (AKBA) stock is $0.980. The stock price is +3.77% higher in the session. The intraday range can be seen from this page. Volume of Akebia Therapeutics, Inc. (AKBA) stock is 12.84M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Akebia Therapeutics, Inc. (AKBA) stock price going up or down today?

The stock price of Akebia Therapeutics, Inc. (AKBA) can change with earnings, company news, and overall market sentiment. Akebia Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Akebia Therapeutics, Inc. stock expensive at its current price?

Whether Akebia Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for AKBA on this page is -10.00. EPS on this page is -0.10. Compare those figures with peers and growth expectations before deciding if the current Akebia Therapeutics, Inc. price is justified.

How has the stock price of Akebia Therapeutics, Inc. (AKBA) performed historically?

Historical performance for Akebia Therapeutics, Inc. (AKBA) is shown on the price chart on this page. Review multi-period moves alongside volume to see how AKBA reacted to past earnings and market events.

Should I buy Akebia Therapeutics, Inc. (AKBA) stock, at this price?

Buying Akebia Therapeutics, Inc. (AKBA) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.